Antje Mevius1, Florian Karl2, Margarethe Wacker2, Robert Welte2, Stefanie Krenzer2, Theresa Link3,4,5,6,7, Ulf Maywald8, Thomas Wilke9. 1. IPAM e.V, University of Wismar, Wismar, Germany. antje.mevius@ipam-wismar.de. 2. GSK, Munich, Germany. 3. Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany. 4. National Center for Tumor Diseases (NCT/UCC), Dresden, Germany. 5. German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 7. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. 8. AOK PLUS, Dresden, Germany. 9. IPAM e.V, University of Wismar, Wismar, Germany.
Abstract
PURPOSE: Endometrial cancer (EC) is the sixth most common malignancy among females worldwide. Due to limited therapeutic options, treatment of advanced or recurrent disease is associated with poor outcomes. The aim of this study was to describe the real-world treatment of patients with advanced or recurrent EC who received a systemic treatment following platinum-based chemotherapy. METHODS: This retrospective cohort study was based on anonymized German claims data covering the period between January 1, 2010, and June 30, 2020. Patients with EC who started an anticancer treatment following platinum-based chemotherapy were observed for a minimum follow-up of 12 months. Available claims data were used to describe patient characteristics, subsequent treatment lines, healthcare resource utilization, and overall survival (OS) of patients. RESULTS: Out of 713 patients with advanced or recurrent EC and who had received a platinum-based treatment, 201 (mean age: 68.9 years) with a post-platinum-based treatment were identified and observed. The median OS in this population was 335.0 days. Of the 201 patients, 79 patients (39.3%) received a second line of treatment (LOT), and 21 patients (10.4%) had 3 or more treatment lines. In the LOTs following platinum-based chemotherapy, more than 70 different treatment regimens were observed. The hospitalization rate was generally high, with 5.2 hospitalizations per patient-year in the follow-up period. CONCLUSION: The wide variety of therapeutic regimens applied in patients in Germany who progressed after platinum-based therapy confirms the lack of therapeutic strategy for these patients, and the poor prognosis highlights the urgent need for new treatment strategies.
PURPOSE: Endometrial cancer (EC) is the sixth most common malignancy among females worldwide. Due to limited therapeutic options, treatment of advanced or recurrent disease is associated with poor outcomes. The aim of this study was to describe the real-world treatment of patients with advanced or recurrent EC who received a systemic treatment following platinum-based chemotherapy. METHODS: This retrospective cohort study was based on anonymized German claims data covering the period between January 1, 2010, and June 30, 2020. Patients with EC who started an anticancer treatment following platinum-based chemotherapy were observed for a minimum follow-up of 12 months. Available claims data were used to describe patient characteristics, subsequent treatment lines, healthcare resource utilization, and overall survival (OS) of patients. RESULTS: Out of 713 patients with advanced or recurrent EC and who had received a platinum-based treatment, 201 (mean age: 68.9 years) with a post-platinum-based treatment were identified and observed. The median OS in this population was 335.0 days. Of the 201 patients, 79 patients (39.3%) received a second line of treatment (LOT), and 21 patients (10.4%) had 3 or more treatment lines. In the LOTs following platinum-based chemotherapy, more than 70 different treatment regimens were observed. The hospitalization rate was generally high, with 5.2 hospitalizations per patient-year in the follow-up period. CONCLUSION: The wide variety of therapeutic regimens applied in patients in Germany who progressed after platinum-based therapy confirms the lack of therapeutic strategy for these patients, and the poor prognosis highlights the urgent need for new treatment strategies.
Authors: Dario Sambunjak; Jason W Nickerson; Tina Poklepovic; Trevor M Johnson; Pauline Imai; Peter Tugwell; Helen V Worthington Journal: Cochrane Database Syst Rev Date: 2011-12-07
Authors: Rebecca A Brooks; Gini F Fleming; Ricardo R Lastra; Nita K Lee; John W Moroney; Christina H Son; Ken Tatebe; Jennifer L Veneris Journal: CA Cancer J Clin Date: 2019-05-10 Impact factor: 508.702
Authors: N Colombo; C Creutzberg; F Amant; T Bosse; A González-Martín; J Ledermann; C Marth; R Nout; D Querleu; M R Mirza; C Sessa Journal: Ann Oncol Date: 2015-12-02 Impact factor: 32.976
Authors: Nicole Concin; Xavier Matias-Guiu; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio Gonzalez Martin; Sigurd Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina Sturdza; Alexandra Taylor; Anneke Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Carien L Creutzberg Journal: Int J Gynecol Cancer Date: 2020-12-18 Impact factor: 3.437